These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8637241)

  • 1. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
    Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
    Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
    Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
    Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
    Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
    Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
    McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
    Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
    Caron PC; Lai LT; Scheinberg DA
    Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
    Caron PC; Dumont L; Scheinberg DA
    Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
    Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
    J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
    Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
    J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
    Borthakur G; Rosenblum MG; Talpaz M; Daver N; Ravandi F; Faderl S; Freireich EJ; Kadia T; Garcia-Manero G; Kantarjian H; Cortes JE
    Haematologica; 2013 Feb; 98(2):217-21. PubMed ID: 22875630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
    Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
    Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model.
    Xu Y; Scheinberg DA
    Clin Cancer Res; 1995 Oct; 1(10):1179-87. PubMed ID: 9815910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
    Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
    Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
    Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
    J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
    Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
    Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
    Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.